Abstract 4561
Background
Discrepancies in perception of adverse events between patients and physicians may influence the follow up services of cancer patients. With patient ratings as the gold standard, physicians more often underrate the symptom severities. In breast cancer (BC) populations, studies of interrater agreement are deficient. We evaluated the agreement between BC patients and their oncologists on the rating of symptoms and functioning in a clinical follow-up study at Trondheim University Hospital.
Methods
At five clinical controls during the first year after primary treatment BC patients (n = 250) and their oncologist (n = 14) reported symptoms and functions by completing the EORTC QLQ-C30/QLQ-BR23 and CTCAE questionnaires, respectively. Fatigue, hot flushes, breast pain, arm pain, emotional and physical functioning were comparable and scored on a four point Likert scale: not at all, mild, moderate and severe. The degree of agreement was evaluated by the Kappa(κ) coefficient. The McNemar-Bowker Test was used to test for association between raters and rating outcome.
Results
Four symptoms and two functions were assessed five times. Of 35 assessments, poor agreement (κ < 0.20) was identified on 24 assessments, fair agreement (0.21< κ > 0.40) on 10 assessments and moderate agreement (κ = 0.41) on one assessment (physical function). Overall, the oncologists rated the severity of all symptoms and the functions significantly lower than the patients (p < 0.01). The agreement decreased with increasing symptom severity and function impairment.
Conclusions
Discrepancies in reporting symptom severity between patients and oncologists might be due to high subjectiveness of symptoms and different understanding of the construct being measured. Personal characteristics of both raters, the context of the clinical controls and the nature of the relationship between patients and physicians may also contribute to discrepancies. Our results emphasize the importance of collecting patient reported data during follow up after BC treatment as it may improve diagnosis and treatment of adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NTNU, Department of Circulation and Medical Imaging, the authors.
Funding
Norwegian University of Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract